ArticleiScience2026

Safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base.

Masayuki Aboshi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.